JP2020507328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507328A5 JP2020507328A5 JP2019543761A JP2019543761A JP2020507328A5 JP 2020507328 A5 JP2020507328 A5 JP 2020507328A5 JP 2019543761 A JP2019543761 A JP 2019543761A JP 2019543761 A JP2019543761 A JP 2019543761A JP 2020507328 A5 JP2020507328 A5 JP 2020507328A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- sequence
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 101
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 102000004169 proteins and genes Human genes 0.000 claims description 64
- 239000000427 antigen Substances 0.000 claims description 50
- 102000036639 antigens Human genes 0.000 claims description 50
- 108091007433 antigens Proteins 0.000 claims description 50
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 20
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 20
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims description 20
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 20
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 6
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 6
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 6
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 claims description 3
- 201000003444 follicular lymphoma Diseases 0.000 claims description 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 2
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000001608 potassium adipate Substances 0.000 claims description 2
- 239000001601 sodium adipate Substances 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 241000282412 Homo Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022196214A JP2023029988A (ja) | 2017-02-10 | 2022-12-08 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457780P | 2017-02-10 | 2017-02-10 | |
| US62/457,780 | 2017-02-10 | ||
| PCT/US2018/017653 WO2018148566A1 (en) | 2017-02-10 | 2018-02-09 | Proteins binding bcma, nkg2d and cd16 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022196214A Division JP2023029988A (ja) | 2017-02-10 | 2022-12-08 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020507328A JP2020507328A (ja) | 2020-03-12 |
| JP2020507328A5 true JP2020507328A5 (OSRAM) | 2021-03-25 |
| JPWO2018148566A5 JPWO2018148566A5 (OSRAM) | 2022-12-26 |
| JP7257323B2 JP7257323B2 (ja) | 2023-04-13 |
Family
ID=63107848
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543761A Active JP7257323B2 (ja) | 2017-02-10 | 2018-02-09 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
| JP2022196214A Pending JP2023029988A (ja) | 2017-02-10 | 2022-12-08 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022196214A Pending JP2023029988A (ja) | 2017-02-10 | 2022-12-08 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190375838A1 (OSRAM) |
| EP (1) | EP3579876A4 (OSRAM) |
| JP (2) | JP7257323B2 (OSRAM) |
| KR (2) | KR20190115469A (OSRAM) |
| CN (1) | CN110461361A (OSRAM) |
| AU (1) | AU2018219348A1 (OSRAM) |
| BR (1) | BR112019016424A2 (OSRAM) |
| CA (1) | CA3054642A1 (OSRAM) |
| IL (1) | IL268567A (OSRAM) |
| MA (1) | MA47465A (OSRAM) |
| MX (1) | MX2019009566A (OSRAM) |
| MY (1) | MY205850A (OSRAM) |
| SG (1) | SG11201907253VA (OSRAM) |
| WO (1) | WO2018148566A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2945620C (en) * | 2014-04-14 | 2022-12-06 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| IL268554B2 (en) | 2017-02-08 | 2025-03-01 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| SG11201907253VA (en) * | 2017-02-10 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding bcma, nkg2d and cd16 |
| CA3235295C (en) | 2017-02-20 | 2024-11-19 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| RU2020111554A (ru) * | 2017-08-23 | 2021-09-23 | Драгонфлай Терапьютикс, Инк. | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген |
| US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
| US12384847B2 (en) | 2018-02-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen |
| US12215157B2 (en) | 2018-02-20 | 2025-02-04 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MA53284A (fr) | 2018-08-08 | 2022-01-26 | Dragonfly Therapeutics Inc | Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| UY38700A (es) * | 2019-05-20 | 2020-12-31 | Novartis Ag | Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso |
| TW202208428A (zh) | 2020-05-06 | 2022-03-01 | 美商蜻蜓醫療公司 | 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質 |
| WO2021248005A1 (en) | 2020-06-05 | 2021-12-09 | Eisai R&D Management Co., Ltd. | Anti-bcma antibody-drug conjugates and methods of use |
| CN112029001B (zh) * | 2020-09-02 | 2022-09-06 | 南京北恒生物科技有限公司 | 靶向nk激活性受体的嵌合抗原受体 |
| AU2021357841A1 (en) * | 2020-10-08 | 2023-06-15 | Affimed Gmbh | Trispecific binders |
| CA3210650A1 (en) | 2021-03-03 | 2022-09-09 | Winfried Wels | Bispecific antibodies enhancing cell mediated immune responses |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| US20240182582A1 (en) * | 2021-03-31 | 2024-06-06 | Janssen Biothech, Inc. | Materials and methods for immune effector cells redirection |
| WO2024020577A2 (en) * | 2022-07-22 | 2024-01-25 | Fred Hutchinson Cancer Center | Antibodies against sars-cov-2 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1909832A4 (en) * | 2005-06-29 | 2010-01-13 | Univ Miami | ANTIBODY IMMUNOCELL LIGAND FUSION PROTEIN FOR CANCER THERAPY |
| EP2418223A3 (en) * | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
| ES2563027T3 (es) * | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| EP2306234A3 (de) * | 2009-10-02 | 2011-06-22 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Optischer Aliasfilter, Pixelsensoranordnung und digitale Aufnahmevorrichtung |
| EA201791693A1 (ru) * | 2011-03-25 | 2018-05-31 | Гленмарк Фармасьютикалс С.А. | Гетеродимерные иммуноглобулины |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| KR102677704B1 (ko) * | 2012-05-30 | 2024-06-21 | 추가이 세이야쿠 가부시키가이샤 | 표적 조직 특이적 항원 결합 분자 |
| CN104395339A (zh) * | 2012-06-27 | 2015-03-04 | 弗·哈夫曼-拉罗切有限公司 | 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途 |
| JP2016507523A (ja) * | 2013-02-05 | 2016-03-10 | エンクマフ アーゲー | ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体 |
| WO2014179363A1 (en) * | 2013-04-29 | 2014-11-06 | Adimab, Llc | Polyspecificity reagents, methods for their preparation and use |
| WO2015197582A1 (en) * | 2014-06-27 | 2015-12-30 | Innate Pharma | Monomeric multispecific antigen binding proteins |
| JP7054622B2 (ja) * | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置 |
| US10973914B2 (en) * | 2015-02-20 | 2021-04-13 | Ohio State Innovation Foundation | Bivalent antibody directed against NKG2D and tumor associated antigens |
| KR102788389B1 (ko) * | 2015-04-06 | 2025-03-31 | 서브도메인, 엘엘씨 | 드 노보 결합 도메인 함유 폴리펩티드 및 그의 용도 |
| JP7082604B2 (ja) * | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
| WO2018148447A1 (en) * | 2017-02-08 | 2018-08-16 | Adimab, Llc | Antibody heavy chain variable domains targeting the nkg2d receptor |
| IL268554B2 (en) * | 2017-02-08 | 2025-03-01 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| SG11201907253VA (en) * | 2017-02-10 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding bcma, nkg2d and cd16 |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
-
2018
- 2018-02-09 SG SG11201907253VA patent/SG11201907253VA/en unknown
- 2018-02-09 AU AU2018219348A patent/AU2018219348A1/en not_active Abandoned
- 2018-02-09 BR BR112019016424A patent/BR112019016424A2/pt not_active Application Discontinuation
- 2018-02-09 WO PCT/US2018/017653 patent/WO2018148566A1/en not_active Ceased
- 2018-02-09 KR KR1020197026174A patent/KR20190115469A/ko not_active Ceased
- 2018-02-09 US US16/484,936 patent/US20190375838A1/en active Pending
- 2018-02-09 CA CA3054642A patent/CA3054642A1/en active Pending
- 2018-02-09 JP JP2019543761A patent/JP7257323B2/ja active Active
- 2018-02-09 MX MX2019009566A patent/MX2019009566A/es unknown
- 2018-02-09 MA MA047465A patent/MA47465A/fr unknown
- 2018-02-09 EP EP18750616.7A patent/EP3579876A4/en active Pending
- 2018-02-09 KR KR1020247004861A patent/KR20240078657A/ko not_active Ceased
- 2018-02-09 CN CN201880021558.4A patent/CN110461361A/zh active Pending
- 2018-02-09 MY MYPI2019004552A patent/MY205850A/en unknown
-
2019
- 2019-08-07 IL IL268567A patent/IL268567A/en unknown
-
2022
- 2022-12-08 JP JP2022196214A patent/JP2023029988A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020507328A5 (OSRAM) | ||
| JP2020510646A5 (OSRAM) | ||
| JP2023052214A5 (OSRAM) | ||
| JP2020508997A5 (OSRAM) | ||
| JP2020507577A5 (OSRAM) | ||
| JP2023106433A5 (OSRAM) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2020521448A5 (OSRAM) | ||
| JP2021098733A5 (OSRAM) | ||
| JP2021098732A5 (OSRAM) | ||
| JP2020529410A5 (OSRAM) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2020522474A5 (OSRAM) | ||
| JP2018500014A5 (OSRAM) | ||
| JP2024167313A5 (OSRAM) | ||
| RU2019129511A (ru) | Белки, связывающие gd2, nkg2d и cd16 | |
| JP2011509245A5 (OSRAM) | ||
| RU2008129080A (ru) | Средства и способы лечения опухолевых заболеваний | |
| JP2020522473A5 (OSRAM) | ||
| RU2021110369A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| JP2019536430A5 (OSRAM) | ||
| JPWO2020033702A5 (OSRAM) | ||
| FI3582806T3 (fi) | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja | |
| JP2020514277A5 (OSRAM) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 |